| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/02/2005 | US20050119195 Gastrointestinal disorders |
| 06/02/2005 | US20050119194 Side effect reduction |
| 06/02/2005 | US20050119193 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same |
| 06/02/2005 | US20050119192 Crystals of glucopyranosyloxybenzyl benzene derivative |
| 06/02/2005 | US20050119191 Induction apoptosis; oxidation resistance; preservatives |
| 06/02/2005 | US20050119190 Anticoagulants; cardiovascular disorders; thrombosis |
| 06/02/2005 | US20050119188 Method of treating breast cancer |
| 06/02/2005 | US20050119177 Using diketopiperazine; graft versus host disease; autoimmune disease; multiple sclerosis; skin disorders; antiarthritic agents; pancreatitis; inflamamtory bowel disorders |
| 06/02/2005 | US20050119170 Therapy for anaphylactic shock |
| 06/02/2005 | US20050119168 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease |
| 06/02/2005 | US20050119164 Immunomodulatory polymeric antigens for treating inflammatory pathogies |
| 06/02/2005 | US20050119162 Anxiolytic agents; using transferrins; quality of life for cancer patients; antiarthritic agents; antiinflammatory agents; compaction; uniform particle size |
| 06/02/2005 | US20050119160 Administering pyrimidopyrimidine compound such as dipyridamole with methotrexate or aspirin |
| 06/02/2005 | US20050119159 Remedy for ischemic heart failure |
| 06/02/2005 | US20050118701 Large scale methods of producing adenovirus and adenovirus seed stocks |
| 06/02/2005 | US20050118694 Culturing microorganism under aerobic conditions and generating preferential biopolymer particle; nutraceuticals; vitamins |
| 06/02/2005 | US20050118622 Methods for predicting development of insulin resistance |
| 06/02/2005 | US20050118586 Expression vector comprising nucleotide sequences coding heterologous polypeptide for use in forensic analysis as chromosome, tissue, cell and organelle specific markers |
| 06/02/2005 | US20050118573 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses |
| 06/02/2005 | US20050118565 Systems and methods for assessing neuronal degeneration |
| 06/02/2005 | US20050118562 Methods for minimizing spasticity in blood vessel grafts |
| 06/02/2005 | US20050118420 Method for configuring air-core photonic-bandgap fibers free of surface modes |
| 06/02/2005 | US20050118299 Companion animal compositions comprising short chain oligofructose |
| 06/02/2005 | US20050118294 Composition for weight reduction comprising water-soluble low-molecular weight chitosan and hibiscus extract |
| 06/02/2005 | US20050118291 Synergistic Effects; preventative effects of Morinda citrifolia-containing compounds on mammary gland tumorigenesis |
| 06/02/2005 | US20050118290 Compositions and method for treatment of steroid/nuclear receptor-mediated diseases |
| 06/02/2005 | US20050118288 Method for producing high-quality hydropbic licorice extract |
| 06/02/2005 | US20050118287 nasal or mouth spray; Extract of Alpinia galanga Rhizomes; Preferably, the vallinoid is selected from the group comprising capsaicin, piperine, gingerols and shogaols |
| 06/02/2005 | US20050118286 comprising an anticonvulsant and a neuroactive modulator; eg childhood disorders, cognitive disorders, substance disorders, schizophrenia, psychotic disorders mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, sexual disorders, gender identity disorders |
| 06/02/2005 | US20050118284 Soluble isoflavone compositions |
| 06/02/2005 | US20050118282 Compositions and methods for inhibiting 5-alpha reductase |
| 06/02/2005 | US20050118281 Substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent. |
| 06/02/2005 | US20050118278 Pharmaceutical or cosmetic composition, preventing or reducing itch and local reaction from stings of insects |
| 06/02/2005 | US20050118276 Coated metal pyrithione particles for treatment of microorganisms |
| 06/02/2005 | US20050118272 Micronized pharmaceutical or nutraceutical powder with immediate release |
| 06/02/2005 | US20050118268 Timed pulsatile drug delivery systems |
| 06/02/2005 | US20050118267 Chronotherapeutic dosage forms |
| 06/02/2005 | US20050118266 pharmaceutically active agent intermixed with a pharmaceutically acceptable water-insoluble, but water-permeable polymeric material; with a second component comprising a mixture of a pharmaceutically active agent and at least 2% (w/w) of a water-insoluble, water-impermeable hydrophobic material |
| 06/02/2005 | US20050118265 Antifungal oral dosage forms and the methods for preparation |
| 06/02/2005 | US20050118264 matrix tablet dosage form, in which Venlaxfaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with a polymeric layer which enables the controlled release; antidepressant |
| 06/02/2005 | US20050118263 Composition |
| 06/02/2005 | US20050118261 Compositions and methods of administering doxepin to mucosal tissue |
| 06/02/2005 | US20050118259 stabilized by use of excipients comprising a basic compound, preferably an alkali-oralkaline earth metal carbonate, and an insoluble alkaline-earth metal carbonate, and an insoluble alkaline-earth metal hydrogen phosphate |
| 06/02/2005 | US20050118257 Dosing a hyperlipidemic with an effective anticholesterol amount of nicotinic acid once per day in the evening or at night; combined with a pharmaceutically acceptable carrier to form an oral solid dosage form; side effect reduction |
| 06/02/2005 | US20050118256 Extended release alpha-2 agonist pharmaceutical dosage forms |
| 06/02/2005 | US20050118253 comprising a nucleic acid that is fully encapsulated within a lipid; for treating a neoplasia in a mammal |
| 06/02/2005 | US20050118250 Lipid carrier compositions with enhanced blood stability |
| 06/02/2005 | US20050118247 Method of making ketoprofen patch delivery system |
| 06/02/2005 | US20050118244 penetration promoter; hormone replacement therapy; contraception |
| 06/02/2005 | US20050118243 Method and composition for delivering zinc to the nasal membrane |
| 06/02/2005 | US20050118242 Using testosterone; topical applying to skins |
| 06/02/2005 | US20050118235 Dietary non-essential amino acid tyrosine regulates the body weight of animals through regulating the animal appetite or food intake |
| 06/02/2005 | US20050118232 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
| 06/02/2005 | US20050118227 Hydrazide compounds with angiogenic activity |
| 06/02/2005 | US20050118226 Sustained-release implant releases ACAT inhibitor for a time effective to reduce ACAT activity; Alzheimer's disease, atherosclerosis; amyloid- beta reduction |
| 06/02/2005 | US20050118221 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
| 06/02/2005 | US20050118219 1,3,6-trihydroxy-7-methoxy-2,8-di (3-methyl-2-butenyl) xanthone; rosacea and/or telangiectasia, skin aging |
| 06/02/2005 | US20050118217 Rapidly disintegrating films for delivery of pharmaceutical of cosmetic agents |
| 06/02/2005 | US20050118208 11-, 13-octadecadienoic acid isomers, 8-, 10-octadecadienoic acid isomers; foods, food supplements, feedstuffs, feed additives, pharmaceutical, cosmetic preparations |
| 06/02/2005 | US20050118206 A surfactant, a solvent, and a beneficial agent; exposure to a hydrophilic environment, surfactant and solvent form a viscous gel and beneficial agent dispersed or dissolved in the gel; |
| 06/02/2005 | US20050118205 Artificial sweetener, a sugar sweetener and a flavoring agent to mask a bitter antibiotic such as levofloxacin |
| 06/02/2005 | US20050118202 Keeping the equilibrium moisture content at 10% or above and/or adding ascorbic acid or a salt thereof to stabilize fused nitrogen heterocyclic ring compounds e.g. 5,6-dimethoxy-2-[2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihydro-1-benzofuran-5-yl]isoindoline,a potential drug for neurodegeneration |
| 06/02/2005 | US20050118198 Polysaccharide vaccine for staphylococcal infections |
| 06/02/2005 | US20050118195 Virus causing respiratory tract illness in susceptible mammals |
| 06/02/2005 | US20050118187 Combinations and methods for treating neoplasms |
| 06/02/2005 | US20050118180 Synergistic mixture with an alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and/or a biologic agent |
| 06/02/2005 | US20050118178 Use of t-cell immune response cdna7 (tirc7) in angiogenic and anti-angiogenic therapy |
| 06/02/2005 | US20050118177 Method for the improvement of neuronal regeneration |
| 06/02/2005 | US20050118172 Humanized antibody CAMPATH-1H administered with steroid (hydrocortisone) |
| 06/02/2005 | US20050118168 Administering a compound which binds to a C-type lectin on the surface of a dendritic cell, with the proviso that the C-type lectin is not the DEC-205 receptor |
| 06/02/2005 | US20050118157 Treatment of central nervous system damage |
| 06/02/2005 | US20050118153 Orally or parenterally administrable; comprises L-carnitine inner salt, acetyl L-carnitine inner salt, alpha -lipoic acid, coenzyme Q10, Vitamin E and selenomethionine; for reducing oxidative stress; apoptosis |
| 06/02/2005 | US20050118150 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine |
| 06/02/2005 | US20050118135 System and methods for inducing ischemia in cells |
| 06/02/2005 | US20050118119 N-( omega -undecylenoyl)phenylalanine; adenylate cyclase inhibitor that has an affinity for the melanocyte specific hormone receptor |
| 06/02/2005 | US20050118118 Nontoxic immunostimulants similar in structure to the lipopolysaccharides of Neisseria meningitidis as sunscreen agents in cosmetics; age resistance |
| 06/02/2005 | US20050118117 Methods for identifying risk of melanoma and treatments thereof |
| 06/02/2005 | US20050118110 Uniform delivery; pressure adjustment and flow accelerating unit |
| 06/02/2005 | US20050118109 Method for treating lung diseases associated with ventilation-perfusion mismatches |
| 06/02/2005 | US20050118107 Formoterol combined with polyvinylpyrrolidone, polyethylene glycol, HFA 227 and HFA 134a; stable in pressurized meter dosage interior coated cans fitted with retention valve |
| 06/02/2005 | US20050118101 Delivery across skin or blood brain barrier; such as N-(fluorescein-5-yl)-thioureido-N'-Adoa-(polylysine)7-NH2 TFA salt |
| 06/02/2005 | US20050116649 Low-pressure mercury vapor discharge lamp |
| 06/02/2005 | DE10352602A1 Kosmetisches oder therapeutisches Kombinationspräparat Cosmetic or therapeutic combination product |
| 06/02/2005 | DE10351271A1 Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz A pharmaceutical composition for the treatment of stress incontinence and / or mixed incontinence |
| 06/02/2005 | DE10350717A1 Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse Use of tyrosine kinase inhibitors for treating inflammatory processes |
| 06/02/2005 | DE10350256A1 PIM-1-spezifische siRNA-Verbindungen PIM-1 specific siRNA compounds |
| 06/02/2005 | CA2807475A1 Inhibitors of the mutant form of kit |
| 06/02/2005 | CA2588012A1 Stable liposome compositions comprising lipophilic amine containing pharmaceutical agents |
| 06/02/2005 | CA2556801A1 Methods and agents for inhibiting dynamin-dependent endocytosis |
| 06/02/2005 | CA2554635A1 Compounds, compositions containing such compounds and methods of treatment of autoimmune diseases using such compounds |
| 06/02/2005 | CA2547881A1 Prevention of and countermeasures against viral infection |
| 06/02/2005 | CA2547842A1 Use of 1,3-diaza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 06/02/2005 | CA2546840A1 Immunization against chlamydia infection |
| 06/02/2005 | CA2546836A1 Immunization against chlamydia infection |
| 06/02/2005 | CA2546643A1 Isoflavonoid prodrugs, compositions thereof and therapeutic methods involving same |
| 06/02/2005 | CA2546620A1 Preparation of 1-aza-2-oxa-dibenzo[e,h]azulenes and their use for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 06/02/2005 | CA2546591A1 Use of 3-aza-1-oxa-dibenzo [e,h] azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 06/02/2005 | CA2546590A1 Use of 1,2-diaza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 06/02/2005 | CA2546404A1 Method and composition for treatment or prophylaxis of amyloidosis disorders |
| 06/02/2005 | CA2546396A1 Method and composition for treatment of cutaneous lesions |